Leukemia

The most recent articles from: Leukemia May 2020

Leukemia · May 2020

Interaction kinetics with transcriptomic and secretory responses of CD19-CAR natural killer-cell therapy in CD20 resistant non-hodgkin lymphoma.

We investigated the cytolytic and mechanistic activity of anti-CD19 chimeric antigen receptor natural killer (CD19. CAR. NK92) therapy in lymphoma cell lines (diffuse large B-cell, follicular, and Burkitt lymphoma), including rituximab- and obinutuzumab-resistant cells, patient-derived cells, and a human xenograft model. ⋯ Collectively, CD19. CAR. NK92 was associated with potent anti-lymphoma activity across a host of sensitive and resistant lymphoma cells that involved distinct immuno-biologic mechanisms of cell death.

keep reading… or just mark as read…

Want more great medical articles?

Keep up to date with a free trial of metajournal, personalized for your practice.
1,706,662 articles already indexed!